The influence of pharmacological pretreatment on efficacy of HI-6 oxime in combination with benactyzine in soman poisoning in rats.
1. The influence of pharmacological pretreatment (pyridostigmine, benactyzine and trihexyphenidyle), designated PANPAL, on soman-induced cholinergic and stressogenic effects as well as on the efficacy of antidotal treatment (HI-6 plus obidoxime) in rats was studied. 2. PANPAL prophylaxis significantly decreased soman-induced cholinesterase inhibition in blood, brain and diaphragm as well as stressogenic effects of soman (an increase in plasma corticosterone level and liver tyrosine aminotransferase activity). 3. PANPAL pretreatment did not improve the efficacy of HI-6 in combination with benactyzine on soman-induced anticholinesterase and stressogenic effects. 4. These findings confirm that PANPAL prophylaxis can improve prognosis of soman poisoning especially by protection of cholinesterases.
Kassa
J
J
Purkynĕ Military Medical Academy, Hradec Králové, Czech Republic.
Bajgar
J
J
D000818:Animals; D000931:Antidotes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001535:Benactyzine / Q000008:administration & dosage / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000506:poisoning* / Q000627:therapeutic use; D002801:Cholinesterase Reactivators / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002802:Cholinesterases / Q000097:blood / Q000378:metabolism; D003345:Corticosterone / Q000097:blood; D003964:Diaphragm / Q000187:drug effects / Q000201:enzymology; D004359:Drug Therapy, Combination; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D009768:Obidoxime Chloride / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D010091:Oximes; D011041:Poisoning / Q000188:drug therapy / Q000517:prevention & control; D011726:Pyridinium Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011729:Pyridostigmine Bromide / Q000008:administration & dosage / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012999:Soman / Q000008:administration & dosage / Q000506:poisoning*; D014282:Trihexyphenidyl / Q000008:administration & dosage / Q000627:therapeutic use; D014444:Tyrosine Transaminase / Q000378:metabolism
D000931:Antidotes; D002800:Cholinesterase Inhibitors; D002801:Cholinesterase Reactivators; D018727:Muscarinic Antagonists; D010091:Oximes; D011726:Pyridinium Compounds; D009768:Obidoxime Chloride; D001535:Benactyzine; D014282:Trihexyphenidyl; D012999:Soman; D014444:Tyrosine Transaminase; D002802:Cholinesterases; C022870:asoxime chloride; D011729:Pyridostigmine Bromide; D003345:Corticosterone